JP6006908B2 - Ｉｃｅ阻害化合物およびその使用 - Google Patents

Ｉｃｅ阻害化合物およびその使用 Download PDF

Info

Publication number
JP6006908B2
JP6006908B2 JP2013537894A JP2013537894A JP6006908B2 JP 6006908 B2 JP6006908 B2 JP 6006908B2 JP 2013537894 A JP2013537894 A JP 2013537894A JP 2013537894 A JP2013537894 A JP 2013537894A JP 6006908 B2 JP6006908 B2 JP 6006908B2
Authority
JP
Japan
Prior art keywords
synuclein
ice
disease
compounds
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503191A (ja
JP2014503191A5 (enExample
Inventor
ダグマー リンジ
ダグマー リンジ
グレゴリー エイ． ぺトスコ
グレゴリー エイ． ぺトスコ
クウェン ホァン
クウェン ホァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brandeis University
Original Assignee
Brandeis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brandeis University filed Critical Brandeis University
Publication of JP2014503191A publication Critical patent/JP2014503191A/ja
Publication of JP2014503191A5 publication Critical patent/JP2014503191A5/ja
Application granted granted Critical
Publication of JP6006908B2 publication Critical patent/JP6006908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2013537894A 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用 Expired - Fee Related JP6006908B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41085610P 2010-11-05 2010-11-05
US41085210P 2010-11-05 2010-11-05
US61/410,856 2010-11-05
US61/410,852 2010-11-05
PCT/US2011/059463 WO2012061785A2 (en) 2010-11-05 2011-11-04 Ice inhibiting compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2014503191A JP2014503191A (ja) 2014-02-13
JP2014503191A5 JP2014503191A5 (enExample) 2014-12-18
JP6006908B2 true JP6006908B2 (ja) 2016-10-12

Family

ID=46024857

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537894A Expired - Fee Related JP6006908B2 (ja) 2010-11-05 2011-11-04 Ｉｃｅ阻害化合物およびその使用
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013537895A Expired - Fee Related JP5980790B2 (ja) 2010-11-05 2011-11-04 バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン

Country Status (4)

Country Link
US (3) US20140309172A1 (enExample)
EP (2) EP2635906A4 (enExample)
JP (2) JP6006908B2 (enExample)
WO (2) WO2012061786A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6006908B2 (ja) * 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
EP3215191B1 (en) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
FI3558335T3 (fi) 2016-12-23 2023-07-19 Casp Aid Inc Kaspaasi-1-inhibitio ja sen käyttötarkoituksia neurologisten tilojen ehkäisyyn ja hoitoon
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
WO2019161302A1 (en) * 2018-02-16 2019-08-22 University Of Southern California Biomarkers for parkinson's disease
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1991015577A1 (en) 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
RU2206611C2 (ru) 1991-08-30 2003-06-20 Вертекс Фармасьютикалз Инкорпорейтед ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU1339092A (en) 1991-12-13 1993-07-19 Corvas International, Inc. Reagents for automated synthesis of peptide analogs
AU3479593A (en) 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
CA2129976C (en) 1992-02-21 2002-09-17 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
FR2698984B1 (fr) 1992-12-04 1995-01-06 Commissariat Energie Atomique Procédé et dispositif d'acquisition d'une image à trois dimensions d'un petit objet par palpage lumineux et moyen d'étalonnage pour la mise en Óoeuvre d'une telle acquisition.
CN1118458C (zh) 1994-03-31 2003-08-20 弗特克斯药品有限公司 作为白细胞介素抑制剂的嘧啶基衍生物
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
CA2215211A1 (en) 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
EP0761680A3 (en) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
WO1998001133A1 (en) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
ATE310528T1 (de) 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
CA2268098A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
BR9712987A (pt) 1996-10-11 2000-04-18 Warner Lambert Co Inibidores de enzima de conversão de interleucina-1beta de sulfonamida
EP0932600B1 (en) 1996-10-11 2006-02-08 Warner-Lambert Company Llc Sulfonamide substituted aspartic acid interleukin-1beta converting enzyme inhibitors
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
DK1049703T3 (da) 1998-01-20 2003-06-02 Abbott Gmbh & Co Kg N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2--(4-fluorphenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-L-asparaginsyrealdehyd som en in vivo inhibitor af interleukin-1beta konverterende enzym
KR20010041905A (ko) 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
PL204619B1 (pl) 1998-03-19 2010-01-29 Vertex Pharma Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej
BR9911010A (pt) 1998-05-05 2005-12-06 Warner Lambert Co Inibidores de sucinamida de enzima de conversão da interleucina-1beta
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US6391575B1 (en) * 1999-03-05 2002-05-21 Idun Pharmaceuticals, Inc. Methods for detecting membrane derived caspase activity and modulators thereof
EP1163214A1 (en) 1999-03-16 2001-12-19 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
EP1165490B1 (en) 1999-03-16 2006-08-16 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
ATE344249T1 (de) 1999-07-19 2006-11-15 Merck Frosst Canada Ltd Pyrazinone, diese verbindungen enthaltende zusammenstellungen
PT1163208E (pt) 1999-08-06 2004-08-31 Vertex Pharma Inibidores de caspase e as suas utilizacoes
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
US6689784B2 (en) 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
NZ516918A (en) 2000-05-23 2004-06-25 Vertex Pharma Caspase inhibitors and uses thereof
DE60131160T2 (de) 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
JP2004509120A (ja) 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
EP1341767B1 (en) 2000-11-21 2007-04-11 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
EP1392280A4 (en) 2001-05-10 2005-11-30 Warner Lambert Co ARYLSULFONAMIDE ETHERS AND METHODS OF USE THEREOF
CA2447999C (en) 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
JP2005509028A (ja) 2001-10-09 2005-04-07 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
EP1480999A2 (en) 2002-02-08 2004-12-01 Idun Pharmaceuticals (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
EP1485107A1 (en) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1494700A2 (en) 2002-04-05 2005-01-12 Cytovia, Inc. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
PE20040728A1 (es) 2002-06-28 2004-10-23 Vertex Pharma Inhibidores de caspasa
US7612091B2 (en) 2002-12-20 2009-11-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DK2361928T3 (en) * 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050202508A1 (en) 2003-11-12 2005-09-15 Pasinetti Guilio M. Biomarker for Parkinson's disease
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
ATE531367T1 (de) 2004-09-17 2011-11-15 Whitehead Biomedical Inst Verbindungen, zusammensetzungen und verfahren zur verhinderung einer a-synuklein-vergiftung
RU2007125278A (ru) 2005-02-08 2009-03-20 Зе Скрипс Ресеч Инститьют (Us) Ингибиторы образования амилоидных волокон транстиретина
US20070092889A1 (en) 2005-06-02 2007-04-26 Perlegen Sciences, Inc. Parkinson's disease-related disease compositions and methods
WO2007089548A2 (en) 2006-01-26 2007-08-09 Foldrx Pharmaceuticals, Inc. Compounds and methods for modulating protein trafficking
US20070197453A1 (en) 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
WO2008034016A2 (en) 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins
US8450481B2 (en) 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
EP2300000A1 (en) * 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
US20120276019A1 (en) * 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
WO2010054127A1 (en) 2008-11-05 2010-05-14 Elan Pharmaceuticals, Inc. Methods and agents for stabilizing non-pathological amyloidogenic polypeptides
HRP20150831T1 (hr) * 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
US20130309690A1 (en) * 2010-11-05 2013-11-21 The Brigham And Women's Hospital, Inc. Tetrameric alpha-synuclein as biomarkers
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用

Also Published As

Publication number Publication date
WO2012061786A1 (en) 2012-05-10
EP2635906A4 (en) 2014-04-02
US9116157B2 (en) 2015-08-25
JP2014503191A (ja) 2014-02-13
WO2012061785A2 (en) 2012-05-10
EP2635907A1 (en) 2013-09-11
US20140309172A1 (en) 2014-10-16
JP5980790B2 (ja) 2016-08-31
JP2013543129A (ja) 2013-11-28
WO2012061785A3 (en) 2013-07-04
US20160143985A1 (en) 2016-05-26
EP2635906A2 (en) 2013-09-11
US20130316384A1 (en) 2013-11-28
EP2635907A4 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
JP5980790B2 (ja) バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン
EP0787146B1 (en) Compounds and methods for inhibiting beta-protein filament formation and neurotoxicity
US8124358B2 (en) Methods of screening for compounds that inhibit binding between amyloid-β(Aβ) and FC-γ receptor IIB (FcγRIIb)
US20180022797A1 (en) Transthyretin antibodies and uses thereof
CN110268269A (zh) 使用apoe4基序介导的基因以用于诊断和治疗阿尔茨海默氏病
EP2039367A1 (en) Prophylactic/therapeutic agent for neurodegenerative disease
AU4869399A (en) Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon)
US20170227553A1 (en) Compositions and methods for identifying and treating conditions involving hsf1 activity
JP4242128B2 (ja) 脳アミロイドーシス予防・治療薬のスクリーニング方法
EP2758077B1 (en) Compounds for use in the treatment of alzheimer's disease
WO2004016751A2 (en) Methods of treating neurodegenerative diseases
WO2014065669A1 (en) Methods of treatment and diagnosis for cognitive decline and memory impairment
AU2018287319B2 (en) Modulators of alpha-synuclein
TWI334784B (en) Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders
EP3271377B1 (en) A peptide or collection of peptides derived from amyloid precursor protein
AU760536B2 (en) Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
US10947311B2 (en) VCAM-1 mediated methods and compositions for treating aging-associated impairments
Zhang Role of misfolded SOD1 in neurodegenerative diseases
Shan et al. APP ubiquitination by VHL protein is essential for MVB sorting and lysosomal degradation
Falkon Endo/Lysosomal Uptake and Degradation of Protein Aggregates in Tauopathy
EP4655320A1 (en) Compositions for treating tauopathies and methods of use thereof
Pannaccione et al. Doctorate School in Molecular Medicine Doctorate Program in Neuroscience Coordinator: Prof Lucio Annunziato XXVIII Cycle
Bridel Transgenic Expression of the Amino-terminus of the Prion Protein and Assessment of the Nasal Cavity as an Entry Site for Prions
Butchbach Regulation of glutamate transport by GTRAP3-18 and by lipid rafts
Wang et al. iPSC-induced neurons with the V337M MAPT mutation are selectively vulnerable to caspase-mediated cleavage of tau and apoptotic cell death

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160801

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160910

R150 Certificate of patent or registration of utility model

Ref document number: 6006908

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees